245 related articles for article (PubMed ID: 29773063)
21. Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.
Talhami A; Swed A; Hess S; Ovadia O; Greenberg S; Schumacher-Klinger A; Rosenthal D; Shalev DE; Hurevich M; Lazarovici P; Hoffman A; Gilon C
Front Chem; 2020; 8():532577. PubMed ID: 33282822
[TBL] [Abstract][Full Text] [Related]
22. Backbone cyclization: A new method for conferring conformational constraint on peptides.
Gilon C; Halle D; Chorev M; Selinger Z; Byk G
Biopolymers; 1991 May; 31(6):745-50. PubMed ID: 1718473
[TBL] [Abstract][Full Text] [Related]
23. Design of peptides, proteins, and peptidomimetics in chi space.
Hruby VJ; Li G; Haskell-Luevano C; Shenderovich M
Biopolymers; 1997; 43(3):219-66. PubMed ID: 9277134
[TBL] [Abstract][Full Text] [Related]
24. Computational Opportunities and Challenges in Finding Cyclic Peptide Modulators of Protein-Protein Interactions.
Duffy F; Maheshwari N; Buchete NV; Shields D
Methods Mol Biol; 2019; 2001():73-95. PubMed ID: 31134568
[TBL] [Abstract][Full Text] [Related]
25. The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm.
Ovadia O; Linde Y; Haskell-Luevano C; Dirain ML; Sheynis T; Jelinek R; Gilon C; Hoffman A
Bioorg Med Chem; 2010 Jan; 18(2):580-9. PubMed ID: 20056544
[TBL] [Abstract][Full Text] [Related]
26. Miniaturized proteins: the backbone cyclic proteinomimetic approach.
Kasher R; Oren DA; Barda Y; Gilon C
J Mol Biol; 1999 Sep; 292(2):421-9. PubMed ID: 10493885
[TBL] [Abstract][Full Text] [Related]
27. Transforming conotoxins into cyclotides: Backbone cyclization of P-superfamily conotoxins.
Akcan M; Clark RJ; Daly NL; Conibear AC; de Faoite A; Heghinian MD; Sahil T; Adams DJ; Marí F; Craik DJ
Biopolymers; 2015 Nov; 104(6):682-92. PubMed ID: 26172377
[TBL] [Abstract][Full Text] [Related]
28. Structure and Function of AApeptides.
Bolarinwa O; Nimmagadda A; Su M; Cai J
Biochemistry; 2017 Jan; 56(3):445-457. PubMed ID: 28029249
[TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry insights into antiviral peptidomimetics.
Ding D; Xu S; da Silva-Júnior EF; Liu X; Zhan P
Drug Discov Today; 2023 Mar; 28(3):103468. PubMed ID: 36528280
[TBL] [Abstract][Full Text] [Related]
30. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt).
Tal-Gan Y; Hurevich M; Klein S; Ben-Shimon A; Rosenthal D; Hazan C; Shalev DE; Niv MY; Levitzki A; Gilon C
J Med Chem; 2011 Jul; 54(14):5154-64. PubMed ID: 21650457
[TBL] [Abstract][Full Text] [Related]
31. Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.
Hess S; Ovadia O; Shalev DE; Senderovich H; Qadri B; Yehezkel T; Salitra Y; Sheynis T; Jelinek R; Gilon C; Hoffman A
J Med Chem; 2007 Nov; 50(24):6201-11. PubMed ID: 17983214
[TBL] [Abstract][Full Text] [Related]
32. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units.
Hurevich M; Tal-Gan Y; Klein S; Barda Y; Levitzki A; Gilon C
J Pept Sci; 2010 Apr; 16(4):178-85. PubMed ID: 20196085
[TBL] [Abstract][Full Text] [Related]
33. Virtual screening using combinatorial cyclic peptide libraries reveals protein interfaces readily targetable by cyclic peptides.
Duffy FJ; O'Donovan D; Devocelle M; Moran N; O'Connell DJ; Shields DC
J Chem Inf Model; 2015 Mar; 55(3):600-13. PubMed ID: 25668361
[TBL] [Abstract][Full Text] [Related]
34. Cyclization and Docking Protocol for Cyclic Peptide-Protein Modeling Using HADDOCK2.4.
Charitou V; van Keulen SC; Bonvin AMJJ
J Chem Theory Comput; 2022 Jun; 18(6):4027-4040. PubMed ID: 35652781
[TBL] [Abstract][Full Text] [Related]
35. Peptide-based inhibitors of protein-protein interactions.
Wójcik P; Berlicki Ł
Bioorg Med Chem Lett; 2016 Feb; 26(3):707-713. PubMed ID: 26764190
[TBL] [Abstract][Full Text] [Related]
36. A two-component 'double-click' approach to peptide stapling.
Lau YH; Wu Y; de Andrade P; Galloway WR; Spring DR
Nat Protoc; 2015 Apr; 10(4):585-94. PubMed ID: 25763835
[TBL] [Abstract][Full Text] [Related]
37. Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
Swedberg JE; Schroeder CI; Mitchell JM; Durek T; Fairlie DP; Edmonds DJ; Griffith DA; Ruggeri RB; Derksen DR; Loria PM; Liras S; Price DA; Craik DJ
Eur J Med Chem; 2015 Oct; 103():175-84. PubMed ID: 26352676
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic design of peptide modulators of protein-protein interactions in membranes.
Stone TA; Deber CM
Biochim Biophys Acta Biomembr; 2017 Apr; 1859(4):577-585. PubMed ID: 27580024
[TBL] [Abstract][Full Text] [Related]
39. Topochemical design of bioactive peptides and peptidomimetics.
Goodman M; Ro S; Yamazaki T; Spencer JR; Toy A; Huang Z; He Y; Reisine T
Bioorg Khim; 1992; 18(10-11):1375-93. PubMed ID: 1363715
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic peptides and peptidomimetics.
Kieber-Emmons T; Murali R; Greene MI
Curr Opin Biotechnol; 1997 Aug; 8(4):435-41. PubMed ID: 9265722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
